(Press-News.org) Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves the way for ISM8969 clinical study in the United States. The Phase I clinical trial aims to evaluate safety, tolerability, and pharmacokinetics profiles.
ISM8969 is a novel oral therapeutic candidate developed through Insilico’s Pharma.AI, with best-in-class potential, unique brain penetrant traits, and favorable druggability profiles demonstrated in preclinical studies.
Insilico Medicine has entered into a co-development collaboration agreement with Hygtia Therapeutics, with both parties each holding 50% of the global rights and interests to the program. In return, Insilico is eligible to receive up to $66 million in upfront and milestone payments.
CAMBRIDGE, Mass., January 23, 2026 --- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders, has recently received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA), intended for the treatment of Parkinson’s Disease.
The Phase I clinical trial plans to evaluate the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers, and to identify the optimal dose level(s) to be recommended for further investigation.
“NLRP3 has emerged as a key contributor to chronic neuroinflammation and disease progression in neurodegenerative disorders. A novel NLRP3 inhibitor, ISM8969 with the desired brain penetrant property made possible via our AI-powered design process, offers the potential to advance Parkinson’s Disease treatment to the next generation,” says Carol Satler, MD, PhD, Senior Vice President for Clinical Development, Non-Oncology, Insilico Medicine. “We are excited to get the greenlight from FDA to advance this novel therapeutic to human clinical trials, and we hope to induce a genuine paradigm shift with AI breakthrough in novel drug discovery.”
Excessive activation of NLRP3 triggers overproduction of pro-inflammatory cytokines and chemokines, resulting in sustained inflammation and tissue damage. By inhibiting NLRP3, ISM8969 aims to modulate this pathological inflammation, supporting neuronal survival and function among patients with neurodegenerative diseases. In December 2024, ISM8969 was nominated as an orally administered, potential best-in-class preclinical candidate targeting NLRP3.
It is worth noting that ISM8969 was discovered and optimized using Insilico’s Chemistry42, the comprehensive generative chemistry engine consisting of multiple applications across the drug design and discovery stages. More importantly, with the ability to cross the blood-brain barrier and reach the central nervous system (CNS) directly, ISM8969 establishes its distinctive advantage against CNS disorders including Parkinson’s Disease, apart from a balanced druggability profile and efficacy against inflammation in both inflammatory and chronic disease mice models.
To accelerate the global development of ISM8969, Insilico Medicine has entered into a co-development collaboration agreement with Hygtia Therapeutics. Under the agreement, Insilico grants Hygtia Therapeutics worldwide rights to research, develop, register, manufacture, and commercialize ISM8969, with both parties each holding 50% of the global rights and interests to the program. In return, Insilico is eligible to receive up to $66 million in upfront and milestone payments.
Based on its comprehensive portfolio empowered by Pharma.AI, Insilico has achieved dozens of collaborations with global leading pharma companies including Sanofi, Lilly, Exelixis and Menarini, and the three key license-out deals sum up to a maximum total contract value of up to US $2.1 billion.
Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D. While traditional early-stage drug discovery typically requires an average of 4.5 years, Insilico has nominated 20 preclinical candidates from 2021 to 2024, with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com
Forward-Looking Statements:
This press release contains forward-looking statements relating to the likely future developments in the business of the Company and its subsidiaries, such as expected future events, business prospects or financial performance. The words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends”, “visions”, “schedule” and similar expressions are intended to identify such forward-looking statements. These statements are based on assumptions and analyses made by the Company at the time of this press release in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate under the circumstances. However, whether actual results and developments will meet the current expectations and predictions of the Company is uncertain. Actual results, performance and financial condition may differ materially from the Company’s expectations.
All of the forward-looking statements made in this press release are qualified by these statements. Consequently, the inclusion of forward-looking statements in this press release should not be regarded as representations by the Board or the Company that the plans and objectives will be achieved, and investors should not place undue reliance on such statements.
The Company, its Board, the employees and the agents of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this press release; and (b) no liability for any losses in the event that any of the forward-looking statements do not materialise or turn out to be incorrect.
END
Hepatic steatosis is a core pathological feature of metabolic dysfunction-associated steatotic liver disease (MASLD). It not only drives disease progression to intrahepatic conditions such as cirrhosis but also elevates the incidence and mortality risk of cardiovascular diseases and extrahepatic malignancies. Importantly, hepatic steatosis is reversible in its early stages. Clinical practice guidelines recommend exercise intervention as the primary approach for treating the disease, and the concept of "exercise as medicine" is widely acknowledged.
In recent years, researchers have mainly evaluated how different components of exercise prescriptions affect health ...
A new expert consensus made available online on 10 October 2025 and published in Volume 5, Issue 4 of the journal Intelligent Medicine on 1 November 2025, sets out a structured framework to assess large language models (LLMs) before they are introduced into clinical workflows. The guidance responds to the rapid uptake of artificial intelligence (AI) tools for diagnostic support, medical documentation, and patient communication, and the corresponding need for consistent evaluation of safety, effectiveness, and fairness.
The consensus formalizes retrospective evaluation—testing ...
The rising incidence of cancer worldwide has led to an increasing number of surgeries that involve the removal of lymph nodes. Although these procedures play a major role in cancer staging and preventing the spread of malignancies, they sometimes come with severe long-term consequences. Since lymph nodes do not naturally regenerate once removed, their absence can lead to a condition known as secondary lymphedema. It manifests as chronic swelling, discomfort, and reduced mobility in affected limbs or regions, severely affecting a patient’s quality of life.
Consequently, a major focus within the ...
New research published in Nature Ecology and Evolution reveals significant recent shifts in tree diversity among the tropical forests of the Andes and Amazon, driven by global change.
The study, led by Dr Belen Fadrique from the University of Liverpool, uses 40 years of records on tree species collected by hundreds of international botanists and ecologists in long-term plots to offer comprehensive insights into tree diversity change in the world’s most diverse forests.
Key Findings
At the continental level, ...
Children with spina bifida, a malformation of the spinal cord that can lead to mobility impairments and hydrocephalus — a buildup of fluid in the brain — face significant risk of cognitive difficulties throughout their lives. A new multi-center study led by researchers at Washington University School of Medicine in St. Louis and Michigan Medicine finds that breathing problems during sleep are a widespread but often undetected issue among these babies and raises the possibility that early treatment might significantly improve ...
The North Atlantic Ocean is warming up. Higher temperatures and increased human activity in the region can trigger abrupt changes in marine ecosystems, for example how species are distributed and what they eat.
In a long-term study published in Frontiers in Marine Science, researchers in Canada have examined the diet of three rorqual whale species and how these whales might have adapted their feeding habits as climate change and increasing human presence reshape the ecosystem of the Gulf of St Lawrence (GSL), a seasonally important feeding area for many whale species.
“A ...
Wetland restoration is expanding worldwide, but long-term success often remains uncertain. Most projects rely on short-term, expert monitoring that ends long before restored wetlands stabilize, leaving major gaps in understanding how restored wetlands actually evolve over time. One increasingly discussed way to close these gaps is to extend monitoring beyond professional teams by engaging local communities and citizens in long-term observation.
In a Perspective published (DOI: 10.1016/j.ese.2026.100656) in Environmental Science and Ecotechnology in January 2026, researchers from Aarhus University ...
New University of Hawaiʻi research confirms that “Sharktober” is real, revealing a statistically significant spike in shark bite incidents in Hawaiian waters every October. The study, which analyzed 30 years of data (1995–2024), found that about 20% of all recorded bites occurred in that single month, a frequency far exceeding any other time of the year. Researchers at UH Mānoa’s Hawai‘i Institute of Marine Biology (HIMB) Shark Lab published their findings in Frontiers in Marine Science.
The research, led by HIMB Professor Carl G. Meyer, determined ...
A new computing platform that pairs artificial intelligence (AI) with high performance computing aims to end the bottleneck holding back fusion energy research by speeding the simulations needed to advance the field.
The project — known as the Simulation, Technology, and Experiment Leveraging Learning-Accelerated Research enabled by AI (STELLAR-AI ) — will be led by the U.S. Department of Energy’s (DOE) Princeton Plasma Physics Laboratory (PPPL). STELLAR-AI will expand far beyond the Lab’s walls, however, bringing together national laboratories, universities, technology companies and industry partners to build the computational foundation ...
Global navigation satellite systems (GNSS) are vital for positioning autonomous vehicles, buses, drones, and outdoor robots. Yet its accuracy often degrades in dense urban areas due to signal blockage and reflections. Now, researchers have developed a GNSS-only method that delivers stable, accurate positioning without relying on fragile carrier-phase ambiguity resolution. Tested across six challenging urban scenarios, the approach consistently outperformed existing methods, enabling safer and more reliable autonomous navigation.
Accurately determining position is critical for the safety and reliability of autonomous vehicles and outdoor ...
